2. Academic Validation
  3. Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

  • PLoS One. 2020 Jul 23;15(7):e0236159. doi: 10.1371/journal.pone.0236159.
Paweł Gunerka 1,  Kamila Gala 1,  Martyna Banach 1,  Jakub Dominowski 1,  Joanna Hucz-Kalitowska 1,  Krzysztof Mulewski 1,  Agnes Hajnal 2,  Endre G Mikus 2,  Damian Smuga 1,  Marcin Zagozda 1,  Krzysztof Dubiel 1,  Jerzy Pieczykolan 1,  Beata M Zygmunt 1,  Maciej Wieczorek 1
Affiliations

Affiliations

  • 1 CelonPharma Innovative Drugs Research & Development Department, Celon Pharma S.A., Lomianki, Poland.
  • 2 LabMagister Training and Science Ltd., Budapest, Hungary.
PMID: 32702053 DOI: 10.1371/journal.pone.0236159
Abstract

Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ Inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ Inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.

Figures
Products